We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Netscientific Plc | LSE:NSCI | London | Ordinary Share | GB00BN4R5Q82 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 63.00 | 61.00 | 65.00 | 63.00 | 63.00 | 63.00 | 0.00 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1M | -3.09M | -0.1312 | -4.80 | 14.85M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/7/2016 09:52 | Good to note Stifel replacing Investec. | yasx | |
27/4/2016 22:39 | Not much happening here lack of interest all round. | blueball | |
14/4/2016 15:58 | Video interview with Francois Martelet Francois Martelet, chief executive of NetScientific PLC (LON:NSCI) says the “encouraging&r The company plans to invest a further US$500,000 into PDS Bio after the early-stage study of PDS0101 for human papilloma virus (HPV) related cancers, designed to assess areas such as safety and whether patients can tolerate the drug, was passed. NetScientific has invested US$2.5mln (£1.76mln) in PDS to date and Martelet says the new investment means it will maintain its interest at around 14.85%. | proactivest | |
13/4/2016 08:31 | This really is very undervalued. | yasx | |
05/4/2016 19:48 | Mortimer, That might be the case, although volumes are relatively thin - I had a chat with Vijay Barathan several weeks ago and it seems to me there is a degree of complacency. I am not sure what Woodford makes of it all, but, every other day is punctuated with an appointment at one of the subsidiary groups, or as part of a advisory group or some key opinion leader. All well and good, but there is little about how they will monetise the assets which is what the strategic change in direction was all about in the summer of last year. There are far too many people on the Board, far too many on the management team, and frankly, there has to be a bit of action from Woodford in exerting a bit of pressure to demand answers about the lack of performance on any metric. Woodford might have had a good run over the years, but, in the smallcap space over the past year or two, anything he seems to touch thereafter collapses. | yasx | |
05/4/2016 14:19 | Really disheartening seeing the ongoing selling driving the price down. Doesn't particularly bode well for Thursdays results. | mortimer7 | |
04/4/2016 20:50 | There appears to be a persistent seller wanting out at any price - it is rather strange, but perhaps the seller is privy to something. With a thinly traded share, it is not easy getting out. | yasx | |
03/4/2016 20:58 | Results this week - one hopes that the progress in various parts of the Group will be highlighted and readers will glean the potential magnitude of the sum of the parts valuation if this were ever to be broken up. Certainly, the last assessment from Investec suggested a sum of the parts value of over £25 - I reckon it ought to be higher still. Woodford saw the potential when he waded in at 120p and above. | yasx | |
03/4/2016 13:48 | Still in a downtrend as predicted 7p fair value. | blueball | |
29/3/2016 22:19 | Notice of Results London, UK - 24 March 2016 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic biomedical and healthcare technology group, announces that it will report its final results for the 12 months ended 31 December 2015 on 07 April 2016. An analyst presentation will be held at the offices of Consilium Strategic Communications at 41, Lothbury, EC2R 7HG at 12.00 on 07 April 2016. | bamboo2 | |
17/3/2016 20:22 | What on a non liquidity stk..; () | sfox1 | |
17/3/2016 18:32 | There is a persistent seller - but, the will clear. What is more significant is that the company is making great strides in terms of monetising several of the assets and bringing on board some key opinion leaders who are able to help penetrate key markets. | yasx | |
17/3/2016 12:16 | A big sell this morning under the bid price. | blueball | |
17/3/2016 08:23 | lol sfox. According to Ichimoko trader its a bear kumo sell signal yesterday . Ichimoko is a more reliable platform. | blueball | |
16/3/2016 23:11 | How can you take someone seriously who call's himself "British bulldog's" ?? I mean c'mon seriously blueball you can do better than that ;)) | sfox1 | |
16/3/2016 23:07 | Nonsense,not a technical play..for that you need liquidity..lot's off it..please don't take offence.."very naive" very! | sfox1 | |
16/3/2016 20:41 | The chart is in terminal decline best sell if you ask me. British Bulls are in agreement with me. | blueball | |
16/3/2016 08:09 | Rns..says it all..distinguished ppl have joined advisory board..a small mkt cap ..makes you wonder why | sfox1 | |
15/3/2016 08:14 | A nob brainer more like..lol. | blueball | |
15/3/2016 08:10 | The chart is shaping up nicely - I think investors have missed the significance of the announcement of the 29th of last month. The assets are now being monetised, and with Woodford keen to buy nearly half the Company at 120p and more, well, this is a nil brainer. | yasx | |
14/3/2016 20:51 | Reason's are simple Woodford owns main holding over 40%.. others holding are well to do long term investors academics etc retail investors who are looking 4 low beta high potential. . so premium attached to price..Common sense. .saying that sense isn't very common. .is it ? | sfox1 | |
14/3/2016 20:12 | Fyi there is literally no stock available either way no seller's no buyer's has no availability off stock ..was put through mkt makes last week ..he just said ..hmmm interesting ..something brewing appointment off smith..presidential award 4 co founder and the player aka Woodford. .he is far from stupid..very astute know's his apples from his oranges ;))) | sfox1 | |
14/3/2016 08:30 | @blueball ..you been on the sauce ?? | sfox1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions